pCODR Performance Report

CADTH is pleased to issue the second pan-Canadian Oncology Drug Review (pCODR) performance report.

Through the pCODR process, CADTH reviews cancer drugs and makes reimbursement recommendations to Canada's provincial and territorial public drug plans –— with the exception of Quebec –— and to provincial cancer agencies.

This performance report analyzes pCODR activity from its launch in 2011 to December 31, 2014.

If you have questions about this report, please contact us at [email protected].